Possibility for Application of 99mTc-Methoxyisobutylisonitrile in Assessing the Efficiency of Chemotherapy Cardiotoxicity Prevention

Vladimir Chernov; Tatiana Kravchuk; Roman Zelchan; Dmitriy Podoplekin; Victor Goldberg

doi:10.4028/www.scientific.net/AMR.1084.426

Paper Titles

Neutron and Neutron-Photon Therapy for Head and Neck Cancer
p.409

Non-Invasive Tissue Injury Monitoring Using Bioimpedance Spectroscopy
p.413

Possibilities of Cardiac Scintigraphy with ¹²³I-Iodophen in Patients with Various Forms of Cardiomyopathies
p.417

Possibilities of Radionuclide-Tomo-Ventriculorgraphy with Labeled 99m Technetium of Sodium Diphosphate Decahydrate in Assessing Mechanical Dyssynchrony of Myocardium and Intracardiac Hemodynamics in Ventricular Arrhythmias in Children
p.422

Possibility for Application of ^99mTc-Methoxyisobutylisonitrile in Assessing the Efficiency of Chemotherapy Cardiotoxicity Prevention
p.426

Possibility of Using ^99mTc-Labeled Macro-Aggregates of Serum Albumin and Diethylene Triamine Pentaacetic Acid in the Assessment Lung Ventilation and Perfusion in Patients with Chronic Obstructive Pulmonary Disease and Coronary Artery Disease
p.430

Possibility of Using Nuclear Track Membrane for Ophthalmology
p.434

Possibility of Using ^99mTc-HMPAO in Estimating Long-Term Prognosis of Cerebral Complications of Coronary Artery Bypass Graft
p.438

Possibility to Use the Radiopharmaceutical Based on the Gamma-Aluminum Oxide Labeled with ^99mTc to Identify Sentinel Lymph Nodes in the Experiment
p.443

HomeAdvanced Materials ResearchAdvanced Materials Research Vol. 1084Possibility for Application of...

Possibility for Application of ^99mTc-Methoxyisobutylisonitrile in Assessing the Efficiency of Chemotherapy Cardiotoxicity Prevention

Abstract:

The main focus of the paper is to estimate the possibility of trimethylhydrasine propionate application to prevent an acute doxorubicin-induced cardiotoxicity in breast cancer patients. The study included women with breast cancer. Main group were injected intravenously trimethylhydrasine propionate prior to chemotherapy. For the cancer treatment of these patients doxorubicin was used. All patients were examined by GATE SPECT before starting chemotherapy and 1 hour after the first administration of doxorubicin. After doxorubicin administration in the control group there was a decrease in left ventricular ejection fraction (LVEF), and an increase in left ventricular end-systolic volume. After administration of doxorubicin 40% of patients had a significant reduction in LVEF. Prophylactic use of trimethylhydrasine propionate allows reducing acute doxorubicin-induced cardiotoxicity incidences by 22.5%.

You might also be interested in these eBooks

Radiation and Nuclear Techniques in Material Science

View Preview

Info:

Periodical:

Advanced Materials Research (Volume 1084)

Pages:

426-429

DOI:

https://doi.org/10.4028/www.scientific.net/AMR.1084.426

Citation:

Cite this paper

Online since:

January 2015

Authors:

Vladimir Chernov, Tatiana Kravchuk, Roman Zelchan*, Dmitriy Podoplekin, Victor Goldberg

Keywords:

^99mTc-Methoxyisobutyl Isonitrile, Anthracycline-Induced Cardiotoxicity, Breast Cancer, GATE Single Photon Emission Tomography (SPECT), Prevention of Cardiotoxicity, Trimethylhydrasine Propionate

Export:

RIS, BibTeX

Price:

Permissions CCC:

Request Permissions

Permissions PLS:

Request Permissions

Сopyright:

Citation:

* - Corresponding Author

References

[1] M.G. Matysh T.L. Kravchuk, V.V. Vysotskaya, V.I. Chernov, V.E. Goldberg, Anthracycline-induced cardiotoxicity: mechanisms of development and clinical manifestations, Siberian J. of Oncol. 30 (2008) 66-75 (Russian).

Google Scholar

[2] C. Sesti, B.Z. Simkhovich, I. Kalvinsh, R. Kloner, Mildronate, a novel fatty acid oxidation inhibitor and antianginal agent, reduces myocardial infarct size without affecting hemodynamics, J. Cardiovasc. Pharmacol. 47 (2006) 493-499.

DOI: 10.1097/01.fjc.0000211732.76668.d2

Google Scholar

[3] Y. Hayashi, H. Ishida, M. Hoshiai, K. Hoshiai, T. Kirimoto, T. Kanno, M. Nakano, K. Tajima, H. Miyake, N. Matsuura, H. Nakazawa, MET-88, a gamma-butyrobetaine hydroxylase inhibitor, improves cardiac SR Ca2π uptake activity in rats with congestive heart failure following myocardial infarction, Mol. Cell. Biochem. 209 (2000).

DOI: 10.1023/a:1007093926315

Google Scholar

[4] Y.B. Lishmanov, V.I. Chernov, N.G. Krivonogov, I.Y. Efimova, J.V. Vesnina, K.V. Zavadovsky, S.M. Minin, S.I. Sazonova, V.S. Skuridin, A.N. Pankova, V.V. Saushkin, Y.N. Ilyushenkova, N.Y. Efimova, Radionuclide methods in the diagnosis of cardiovascular diseases, Siberian Med. J. 25 (2010).

Google Scholar

[5] D. Iarussi D, P. Indolfi, F. Casale, V. Martino, M.T. Di Tullio, R. Calabrò, Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management, Paediatr. Drugs. 7(2005) 67-76.

DOI: 10.2165/00148581-200507020-00001

Google Scholar

[6] S.M. Swain, F.S. Whaley, M.C. Gerber, S. Weisberg, M. York, D. Spicer, S.E. Jones, S. Wadler, A. Desai, C. Vogel, J. Speyer, A. Mittelman, S. Reddy, K. Pendergrass, E. Velez-Garcia, M.S. Ewer, J.R. Bianchine, R.A. Gams, Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer, J. Clin. Oncol. 15 (1997).

DOI: 10.1200/jco.1997.15.4.1318

Google Scholar

[7] V.I. Chernov, A.A. Garganeeva, J.V. Vesnina, Y.B. Lishmanov, Myocardial perfusion scintigraphy in the evaluation of the trimetazidine treatment results in patients with ischemic heart disease, J. Cardiol. 40 (2001) 14-16 (Russian).

Google Scholar

[8] N. Sjakste, A.L. Kleschyov, J.L. Boucher, L. Baumane, M. Dzintare, D. Meirena, J. Sjakste, K. Sydow, T. Münzel, I. Kalvinsh, Endothelium- and nitric oxide-dependent vasorelaxing activities of gamma-butyrobetaine esters: possible link to the antiischemic activities of mildronate, Eur. J. Pharmacol. 495 (2004).

DOI: 10.1016/j.ejphar.2004.05.006

Google Scholar